(Total Views: 598)
Posted On: 09/13/2020 1:21:21 PM
Post# of 155727
Re: Riztheinvestor #55553
“Really you think a few years behind?”
At least 18 months, if not more. I spend a few minutes trying to find when the phase 1/2 IMMU trial started for mTNBC, but I couldn’t find it. But that trial, which helped lead to approval, was 140 patients treated for 6-12 months. Can you imagine how long it would take CYDY to enroll 140 patients?
The larger trial for IMMU, which was 500 patients, would take even longer to enroll. So yes, leronlimab is at least 1.5-2 years behind. That could always change if trial data is outstanding, but regardless, measurement of progression free survival requires a trial of at least 6-12 months. The current mTNBC trial does have PFS as an endpoint, but it’s only in 30 patients.
At least 18 months, if not more. I spend a few minutes trying to find when the phase 1/2 IMMU trial started for mTNBC, but I couldn’t find it. But that trial, which helped lead to approval, was 140 patients treated for 6-12 months. Can you imagine how long it would take CYDY to enroll 140 patients?
The larger trial for IMMU, which was 500 patients, would take even longer to enroll. So yes, leronlimab is at least 1.5-2 years behind. That could always change if trial data is outstanding, but regardless, measurement of progression free survival requires a trial of at least 6-12 months. The current mTNBC trial does have PFS as an endpoint, but it’s only in 30 patients.
(0)
(0)
